<p>Novartis AG has agreed to acquire the American biotechnology company Avidity Biosciences for $72 per share, representing a premium of 46%, with a transaction valuation of $12 billion. This move will strengthen its late-stage neuroscience research and development pipeline</p>

<p>Novartis AG agreed to acquire the American biotechnology company Avidity Biosciences for $72 per share, representing a premium of 46%, with a transaction valuation of $12 billion. This move will strengthen its late-stage neuroscience research and development pipeline</p>

快讯